Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts
Mural Oncology plc - Ordinary Shares (MURA)
Company Research
Source: GlobeNewswire
Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Preliminary data readouts for less-frequent intravenous dosing of nemvaleukin in patients with cutaneous melanoma expected in 1H 2025 for monotherapy, with patient enrollment now complete, and 2H 2025 for combination therapy Mural nominated two new development candidates, MURA-8518 a novel binding protein-resistant IL-18 with half-life extension, and MURA-7012, targeted split sub-units of IL-12; Mural anticipates an IND submission for MURA-8518 in Q4 2025 Company extends cash runway projection into Q1 2026 through operational efficiencies WALTHAM, Mass. and DUBLIN, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered therapies targeting cytokine pathways designed to address areas of unmet need
Show less
Read more
Impact Snapshot
Event Time:
MURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MURA alerts
High impacting Mural Oncology plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
MURA
News
- XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc [Yahoo! Finance]Yahoo! Finance
- Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of AcquisitionGlobeNewswire
- Mural Oncology Announces Sanction of the Scheme by the High CourtGlobeNewswire
- Mural Oncology (NASDAQ:MURA) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA RoyaltyGlobeNewswire
MURA
Sec Filings
- 12/5/25 - Form S-8
- 12/5/25 - Form S-8
- 12/5/25 - Form S-8
- MURA's page on the SEC website